NACL Industries Q3 FY26 – ₹318 Cr Revenue, Yet Another Loss, Coromandel Enters the Chat
1. At a Glance – When the Tractor Is Moving but the Engine Is Knocking
NACL Industries currently sits at a market cap of ₹3,565 crore with a stock price of ₹152, down sharply from its euphoric ₹311 high and still far away from its ₹49 panic low. Over the last 3 months, the stock is down ~17%, and over 6 months it’s a brutal -45%, which tells you sentiment has gone from “future agro champ” to “bhai ye kya ho raha hai?”
Latest Q3 FY26 numbers didn’t help calm nerves. Revenue came in at ₹318 crore, up 18.8% YoY, but PAT stayed negative at ₹ -10.2 crore. Operating margin limped in at ~2%, which for an agrochemical company is like opening a fertilizer shop and selling air.
Debt is still chunky at ₹502 crore, ROCE is -7.8%, ROE is -25.8%, and interest coverage is negative. On valuation optics, the stock trades at ~8x book value, despite bleeding profits. That’s not “premium chemistry”, that’s “hope-based valuation”.
And just when retail investors were wondering who will clean this mess, Coromandel International walked in, bought control, launched an open offer at ₹76.70, and basically said: “Step aside, let the adults handle this.”
Curious why a Murugappa Group company wants this headache? Let’s dig in.
2. Introduction – From Nagarjuna Legacy to Corporate ICU
NACL Industries is not some fly-by-night agro startup. This is a legacy agrochemical company with technicals + formulations, exports to 30+ countries, 518 domestic registrations, 120 international registrations, and presence across 55,000+ retail counters.
On paper, this should have been a cash machine.
Instead, FY24–FY26 has looked like a slow-motion stress test. Rising raw material costs, weak export demand, pricing pressure, high interest burden, and working capital swings have turned NACL into a company that sells more but earns less. Sometimes a lot less.
Then came the big event: Coromandel International acquiring ~53% stake, triggering promoter reclassification and a mandatory open offer. This isn’t a financial investor flip. Coromandel is a strategic agro heavyweight.
So the question changes from:
“Is NACL doing well?” to “Can Coromandel fix NACL?”
But before answering that, we need to understand what NACL actually does and where it is bleeding.
3. Business Model – WTF Do They Even Do?
NACL operates across three agrochemical verticals, all of which sound fancy but behave very differently on margins.
a) Domestic Retail Business
This is the farmer-facing business. Crop protection products sold through distributors and retailers. Volume-heavy, brand-dependent, working-capital intensive, and extremely sensitive to monsoon, MSPs, and farmer sentiment.
Margins here are okay in good years, terrible in bad ones.
b) Domestic Institutional (B2B)
This is where NACL supplies formulations and actives to other agro players. Lower branding costs, but pricing power is limited. Think “steady but boring”.
c) Exports Business
Supplying technicals + formulations to MNCs and overseas distributors across 31 countries. Historically a strength. Recently, a pain point due to:
Global destocking
China dumping
Price erosion
Currency mismatches
NACL also does contract manufacturing for MNCs, which is strategically valuable but margin-thin unless scale kicks in.
So yes, the business model is solid. Execution lately? Not so much.
4. Financials Overview – Numbers Don’t Lie, But They Do Roast
Quarterly Comparison Table (₹ crore)
Metric
Latest Q3 FY26
Q3 FY25
Q2 FY26
YoY %
QoQ %
Revenue
318
268
457
18.8%
-30.4%
EBITDA
7
-26
45
NA
-84%
PAT
-10
-36
3
72%
-433%
EPS (₹)
-0.43
-1.56
0.11
NA
NA
Commentary (no mercy):
Revenue grew YoY, but sequentially fell off a cliff.
EBITDA positive but barely breathing.
PAT negative again – consistency matters, unfortunately this is the
